FDA
-
-
-
-
-
-
-
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
-
-
-
-
-
-
-
The Credibility Filter Wall Street Uses to Sort Biotech Winners
-
-
-
-
-
-
-
Intellia Therapeutics (NTLA) PT Raised to $15 at RBC Capital
-
-
-
-
-
-
-
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
-
-
-
-
-
-
-
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
-
-
-
-
-
-
-
FDA Clears Way for Faster Personalized Gene Editing Treatments
-
-
-
-
-
-
-
Intellia completes enrollment in phase 3 study of HAE gene therapy
-
330,345 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

